The audit was conducted in late February by GSK (Great Britain), which is one of the world"s largest medical and pharmaceutical products, has offices and factories in more than 120 countries worldwide. The company has a significant research base and develops drugs for the treatment of dermatological diseases and cancer.

The auditor has examined the manufacturing stage Agidol-1 crystal, from the acceptance of incoming raw materials through all stages of production, to the finished goods warehouse. Particular emphasis was placed on quality assurance of products, documentation, accuracy and reliability of the measurement equipment laboratory studies.

In his closing remarks, the auditor noted the high level of qualification. Knowledge of and fidelity to duty production staff ensures proper operation of the quality management system in the enterprise. Results of the audit confirmed the compliance of the SQM requirements of GSK. This confirmation is valid for the next 5 years, which gives the right of offer a full range of its products to all units of GSK.